Prof. Uriel Heresco-Levy

Uriel Heresco-Levy, MD, is Director of Schizophrenia Research Program and Pychiatry Department at Ezrath Nashim – Herzog Memorial Hospital, and Full Professor at Hadassah Medical School – Hebrew University, Jerusalem, Israel. He trained at Hebrew University, Sacker Medical School – Tel-Aviv University and Albert Einstein College of Medicine – Yeshiva University, New York.

A pioneer in the study of glutamatergic pharmacological treatment approaches, he published extensively on the use of glycine site agonists of the N-methyl-D-aspartate (NMDA) receptor, such as glycine, D-cycloserine and D-serine, as novel treatments for schizophrenia. Dr. Heresco-Levy’s work has been supported by numerous national and international research grants including Stanley Foundation and NARSAD Young and Independent Investigator Awards.

He received the Clinical Research Award of the Israel Society for Biological Psychiatry and is Fellow of Collegium Internationale Neuro – Psychopharmacology (CINP) and member of the European College of Neropsychpharmacology (ECNP). Prof. Heresco-Levy’s main research interests center around:
1) the identification of glutamate systems dysfunctions in schizophrenia and related disorders;
2) the development of novel pharmacological strategies for the treatment of this disorder, based upon the manipulation of NMDA and non-NMDA glutamate receptors – mediated neurotransmission; and
3) the assessment of efficacy and safety of glutamate receptor-based treatment approaches for additional neuropsychiatric disorders, including Parkinson’s disease, major depressive disorder and posttraumatic stress disorder.